title: Diagnostic value of immunohistochemistry for the detection of the BRAFV600E mutation in primary lung adenocarcinoma Caucasian patients.
abstract: BACKGROUND
  Non-small-cell lung carcinoma (NSCLC) patients with a BRAF(V600E) mutation benefit from targeted therapy. The usefulness of immunohistochemistry (IHC) as an alternative approach for the detection of BRAF(V600E) in NSCLC patients has not been evaluated until now. This study compared the specificity and sensitivity of IHC with other methods for the detection of BRAF(V600E) in primary lung adenocarcinoma.
  
  
  METHODS
  BRAF mutations were analysed by DNA sequencing of a Caucasian subpopulation of selected 450 of 1509 (30%) EGFR, KRAS, PI3KA, Her2 and EML4-ALK wild-type (wt) primary lung adenocarcinomas. Detection of the BRAF(V600E) mutation was carried out by IHC using the VE1 clone antibody and compared with the results of other molecular methodologies.
  
  
  RESULTS
  Of 450 (9%) of tumours, 40 harboured a BRAF mutation, which corresponded to either a BRAF(V600E) or a non-BRAF(V600E) mutation in 21 of 450 (5%) and 19 of 450 (4%) cases, respectively. The IHC VE1 assay was positive in 19 of 21 (90%) BRAF(V600E)-mutated tumours and negative in all BRAF(nonV600E)-mutated tumours.
  
  
  CONCLUSIONS
  IHC using the VE1 clone is a specific and sensitive method for the detection of BRAF(V600E) and may be an alternative to molecular biology for the detection of mutations in NSCLC.
authors.affiliation: INSERM U1081/CNRS UMR7284, Team 3, University of Nice Sophia Antipolis, Institute for Research on Cancer and Aging in Nice IRCAN, 06017 Nice cedex, France.
authors.forename: M
authors.initials: M
authors.lastname: Ilie
authors.forename: E
authors.initials: E
authors.lastname: Long
authors.forename: V
authors.initials: V
authors.lastname: Hofman
authors.forename: B
authors.initials: B
authors.lastname: Dadone
authors.forename: C H
authors.initials: CH
authors.lastname: Marquette
authors.forename: J
authors.initials: J
authors.lastname: Mouroux
authors.forename: J M
authors.initials: JM
authors.lastname: Vignaud
authors.forename: H
authors.initials: H
authors.lastname: Begueret
authors.forename: J P
authors.initials: JP
authors.lastname: Merlio
authors.forename: D
authors.initials: D
authors.lastname: Capper
authors.forename: A
authors.initials: A
authors.lastname: von Deimling
authors.forename: J F
authors.initials: JF
authors.lastname: Emile
authors.forename: P
authors.initials: P
authors.lastname: Hofman
mesh_terms: D000230:Adenocarcinoma / Q000175:diagnosis* / Q000235:genetics / Q000378:metabolism / Q000401:mortality; D000077192:Adenocarcinoma of Lung; D000368:Aged; D000369:Aged, 80 and over; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D053208:Kaplan-Meier Estimate; D008175:Lung Neoplasms / Q000175:diagnosis* / Q000235:genetics / Q000378:metabolism / Q000401:mortality; D008297:Male; D008875:Middle Aged; D025202:Molecular Diagnostic Techniques; D015999:Multivariate Analysis; D020125:Mutation, Missense; D016016:Proportional Hazards Models; D048493:Proto-Oncogene Proteins B-raf / Q000235:genetics* / Q000378:metabolism; D044465:White People
chemical_list: C482119:BRAF protein, human; D048493:Proto-Oncogene Proteins B-raf